Managing Patients With Advanced NSCLC Without a Driver Mutation in the Second-Line Setting: Treatment After Checkpoint Inhibitor Therapy

Text Registration

Managing Patients With Advanced NSCLC Without a Driver Mutation in the Second-Line Setting: Treatment After Checkpoint Inhibitor Therapy

Status

Published

on 12 Aug 2019

Year of Creation

2019

Med-IQ, Inc

Registration Number

TX0008780199

on 12 Aug 2019

The U.S. Copyright record (Registration Number: TX0008780199) dated 12 Aug 2019, pertains to an electronic file (eService) titled "Managing Patients With Advanced NSCLC Without a Driver Mutation in the Second-Line Setting: Treatment After Checkpoint Inhibitor Therapy" created in 2019. The copyright holder is Med-IQ, Inc, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to Med-IQ, Inc.

Med-IQ, Inc

Application Details

Registration Number

TX0008780199

Registration Date

8/12/2019

Year of Creation

2019

Agency Marc Code

DLC-CO

Record Status

New

Corporate Author

Med-IQ, Inc

Physical Description

Electronic file (eService)

First Publication Nation

United States

Preexisting Material

References

Corporate Authors

Inc Med-IQ

Notes

Rights Note: Susan Dembeck, Med-IQ, Inc., 5523 Research Park Drive, Ste 210, Baltimore, MD, 21228, United States, (443) 836-6980, sdembeck@med-iq.com

Material Matter Claimed Note: text

Statements

Application Title Statement: Managing Patients With Advanced NSCLC Without a Driver Mutation in the Second-Line Setting: Treatment After Checkpoint Inhibitor Therapy

Author Statement: Med-IQ, Inc employer for hire Domicile: United States Citizenship: United States Authorship: text

Notes

Rights Note: Susan Dembeck, Med-IQ, Inc., 5523 Research Park Drive, Ste 210, Baltimore, MD, 21228, United States, (443) 836-6980, sdembeck@med-iq.com

Material Matter Claimed Note: text

Statements

Application Title Statement: Managing Patients With Advanced NSCLC Without a Driver Mutation in the Second-Line Setting: Treatment After Checkpoint Inhibitor Therapy

Author Statement: Med-IQ, Inc employer for hire Domicile: United States Citizenship: United States Authorship: text

Get your copyright registered todayThousands have copyrighted their assets.
What are you waiting for?

Show terms & conditions

Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.